The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis (Q40896928)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

24 September 2017

The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis (English)

1 reference

Europe PubMed Central

24 September 2017

multiple sclerosis

0 references

author name string

Warren KG

1

1 reference

Europe PubMed Central

24 September 2017

Catz I

2

1 reference

Europe PubMed Central

24 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 1997

1 reference

Europe PubMed Central

24 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

Journal of the Neurological Sciences

1 reference

Europe PubMed Central

24 September 2017

148

1 reference

Europe PubMed Central

24 September 2017

1

1 reference

Europe PubMed Central

24 September 2017

67-78

1 reference

Europe PubMed Central

24 September 2017

Autoantibodies to myelin basic protein are not present in the serum and CSF of MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Antigen-specific interaction between T and B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Molecular mimicry and autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Lymphocyte responses and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Intravenous antigen administration as a therapy for autoimmune demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Major T-cell responses in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

A correlation between cerebrospinal fluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Administration of myelin basic protein synthetic peptides to multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Structure of anti-peptide antibody complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905331-2

7 January 2021

Identifiers

10.1016/S0022-510X(96)05331-2

1 reference

Europe PubMed Central

24 September 2017

1 reference

Europe PubMed Central

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40896928&oldid=1909877434"